

March 31, 2023 | Issue 265

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



FDA <u>approved the first over-the-counter naloxone</u> spray... FDA will <u>convene an advisory panel to review</u> an ALS cell therapy that it previously refused to consider... FDA <u>guidance</u> delays enforcement to October for <u>medical device manufacturers to meet new cybersecurity requirements</u>.

FDA draft <u>guidance recommended</u> oncology drug developers use a single randomized controlled trial <u>to seek accelerated approval</u> and confirm clinical benefit... FDA <u>draft guidance</u> streamlines updates to AI-enabled medical devices.

HRSA is seeking compliance data from several 340B hospitals.

HHS announced \$123.6M in funding to expand behavioral health clinics.

CMS <u>approved NJ's extended/amended section 1115 demonstration</u> to provide <u>housing and nutrition benefits</u> to Medicaid beneficiaries.



Healthcare law and policy news

A <u>federal judge struck down</u> the ACA requirement for coverage without cost sharing of USPSTF-recommended preventive services.

NC <u>enacted legislation making it the 40th state</u> to expand Medicaid... Oklahoma became the <u>30th state plus DC to offer one year of postpartum</u> Medicaid coverage.

The Supreme Court <u>heard arguments</u> in the Amgen v. Sanofi <u>patent</u> <u>dispute</u>... Ohio's Attorney General <u>sued Cigna/Express Scripts</u>, <u>Prime</u> <u>Therapeutics</u>, <u>Humana</u>, <u>and others</u> for <u>allegedly colluding</u> to <u>"illegally drive</u> <u>up drug prices"</u>... LabCorp will <u>pay \$2.1M to settle FCA allegations</u> for overbilling the Defense Department.

CVS completed its <u>acquisition of Signify Health</u>... DOJ and FTC <u>did not</u> <u>take action to block</u> the CVS-Oak Street merger... Sartorius <u>will acquire</u> <u>Polyplus</u> (\$2.6B)... <u>UnitedHealthcare</u> and <u>Cigna</u> are reducing prior authorization requirements... Amazon Pharmacy <u>will automatically apply</u> <u>drug manufacturer coupons</u> directly to brand-name medication orders.

Altarum reported <u>healthcare employment has returned to February 2020</u> <u>levels</u>, although shortages remain for nursing and residential care employment... FAIR Health <u>reported telehealth utilization declined 76%</u> from 2020 to 2021, while utilization at retail clinics increased 51%.

A <u>Holon Solutions survey found 77% of healthcare workers</u> are experiencing burnout and 51% believe their job has gotten more difficult in the past year... A KFF poll found <u>81% of adults are worried</u> "that Medicare will not be able to continue to provide at least the same level of benefits in the future."

Senate Finance Committee <u>held a hearing on the impact of PBMs</u> on patients and taxpayers... House Energy and Commerce Health Subcommittee <u>held a hearing on transparency and competition</u> in healthcare.



President Biden <u>does not plan to veto a resolution</u> to end the COVID-19 national emergency early; the public health emergency (PHE) is still set to expire on May 11.

FDA guidance documents state that: (1) manufacturers of COVID-19 tests and other devices granted emergency use authorization (EUA) <u>will be</u> <u>given approximately 180 days' notice</u> before the EUA is terminated; and, (2) devices that fall within certain enforcement polices, such as ventilators and personal protective equipment, will be <u>withdrawn within 180 days of</u> the end of the public health emergency.

The Biden Administration <u>reported that the Public Health Emergency</u> <u>Medical Countermeasures Enterprise</u>, which includes the Strategic National Stockpile and BARDA, NIH, and FDA countermeasure efforts, will <u>need</u> <u>\$64B in funding over the next five years</u>, but is underfunded by about \$35.3B.

A <u>CDC-CMS-NIH study found</u> patients receiving telehealth drug therapy for opioid use disorder during the pandemic (between September 2019 and February 2021) had 33% lower adjusted odds of a fatal overdose than those not receiving treatment.

A <u>Morning Consult-de Beaumont Foundation poll found</u> 72% of US doctors believe misinformation has made it harder to treat COVID-19 patients and harmed patient outcomes... Trust for America's Health <u>reported</u> nine states improved their public health preparedness in 2022, while nine states' preparedness fell.

Johnson & Johnson will <u>stop work on its investigational RSV adult vaccine</u> <u>program</u> and discontinue the Phase III trial.

53

Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please <u>click here</u>. If you wish to unsubscribe from all KPMG communications, please <u>click here</u>.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.